Published in Vaccine Weekly, November 26th, 2003
Operating income in the first 9 months of 2003 was earned from ongoing smallpox vaccine contracts with the governments of the U.K., Germany, and the U.S. This trend is expected to continue in the fourth quarter. Third-quarter revenue was DKK 232.8 million and a profit before interest and tax of DKK 133.0 million.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly